Aptamer Screening Service-Subtractive SELEX
Info Center
Home » Aptamer » aptamer screening service » Aptamer Screening » Aptamer Screening Service-Subtractive SELEX

Aptamer Screening Service-Subtractive SELEX

Date:2026-01-10

What is Subtractive SELEX?

It is a specialized version of SELEX used to generate aptamers (single-stranded DNA or RNA oligonucleotides) that bind with high affinity and specificity to a target of interest (e.g., a protein, cell, small molecule) while actively excluding binding to closely related non-targets (e.g., a non-pathogenic vs. pathogenic strain, a healthy vs. cancerous cell, or a target in a complex mixture).

The “subtractive” step removes sequences that bind to unwanted counter-targets, ensuring the final aptamer pool is highly specific.


Core Workflow of a Subtractive SELEX Service

A typical service follows these key stages:

1. Project Design & Library Synthesis

  • Client Consultation: Defining the target of interest (e.g., recombinant protein, whole cell) and the critical counter-target(s) for subtraction (e.g., isotype control protein, non-target cell line).

  • Library Design: A service provider synthesizes a vast random-sequence oligonucleotide library (typically 10^14 – 10^15 unique sequences) flanked by constant primer regions.

2. The Subtractive SELEX Cycle (Repeated 8-15 Rounds)
This is the iterative heart of the service:
* a. Negative Selection (Subtraction): The oligonucleotide pool is incubated with the counter-target (or complex background, like serum). Sequences that bind to this unwanted material are discarded.
* b. Positive Selection: The unbound sequences from (a) are then incubated with the target of interest. The bound sequences are recovered.
* c. Washing: Non-specific or weakly bound sequences are washed away.
* d. Elution: The target-bound aptamer candidates are released (e.g., by heat, denaturation, or target-specific elution).
* e. Amplification: The eluted sequences are amplified by PCR (for DNA) or RT-PCR (for RNA). For RNA aptamers, an in vitro transcription step is included.
* f. Purification: The amplified pool is purified for the next round.
* Increasing Stringency: In later rounds, conditions (wash time, salt concentration, target concentration) are made stricter to select for the highest-affinity binders.

3. Sequencing & Bioinformatics

  • High-Throughput Sequencing (HTS): The final enriched pool is sequenced using Next-Generation Sequencing (NGS).

  • Bioinformatic Analysis: Clusters of related sequences are identified. Consensus motifs and secondary structures are predicted. This analysis pinpoints the most promising aptamer candidates, often reducing thousands of sequences to a handful of leads.

4. Characterization & Validation

  • Synthesis: The top candidate sequences (typically 5-10) are chemically synthesized in pure, truncated forms.

  • Affinity Measurement: Binding affinity (Dissociation Constant, Kd) is determined via techniques like Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (BLI), or Flow Cytometry (for cells).

  • Specificity Testing: Critical validation against the original counter-target(s) and other related molecules to confirm the subtractive success.

  • Functionality Assay: Testing in the intended application (e.g., ELISA-type detection, inhibition of protein function, cell staining).


Key Advantages of a Subtractive SELEX Service

  • High Specificity: The primary benefit. Essential for discriminating between targets with high homology (e.g., different post-translational modifications, mutant vs. wild-type proteins).

  • Selection in Relevant Milieu: Allows for selection against a target in a complex background (e.g., a biomarker on a cell surface amidst thousands of other proteins).

  • Reduced Background Binding: Yields aptamers with cleaner performance in diagnostic or therapeutic applications.

  • Discovery of Rare Binders: Can find needles in the haystack that recognize a unique epitope not present on the counter-target.


Typical Applications

  • Biomarker Discovery & Diagnostics: Selecting aptamers for a disease-specific cell (e.g., cancer cell) using healthy cells for subtraction.

  • Therapeutics: Developing aptamers that inhibit a pathogenic virus or bacterial strain without affecting host cells or commensal bacteria.

  • Food/Environmental Safety: Detecting a specific contaminant or pathogen in a complex matrix.

  • Neuroscience: Targeting protein aggregates (e.g., amyloid-beta isoforms) associated with disease.


What to Look for in a Service Provider

Service Aspect Key Questions to Ask
Experience Do they have a proven track record with your target type (proteins, cells, small molecules)?
Design Input Will they collaborate on designing appropriate counter-targets?
Technology Do they use NGS and advanced bioinformatics for analysis? Do they offer modified nucleotides (e.g., 2′-F, 2′-O-Me) for RNA aptamers to enhance stability?
Validation What level of binding characterization (Kd, specificity) is included in the base package?
Timeline & Cost What is the typical timeline (often 3-6 months) and cost structure? Are there options for truncated, stabilized final sequences?
Delivery What is the final deliverable? (Sequence list, synthesized aptamers, full binding data report?)

Conclusion

A Subtractive SELEX Aptamer Screening Service is a powerful solution for obtaining high-specificity molecular recognition elements. By actively removing cross-reactive sequences, it addresses one of the most significant challenges in binder development. When partnering with a service provider, clear communication about the target, counter-target, and intended application is crucial for a successful outcome that delivers aptamers with real-world utility.